Skip to main content
Clinical Trials/NCT02649647
NCT02649647
Recruiting
Not Applicable

Randomized Trial of Sphincter-Preserving Surgery With Proximally Extended Resection Margin on Bowel Function and Anastomotic Complication for Rectal Cancer Patients After Neoadjuvant Chemoradiotherapy

Sixth Affiliated Hospital, Sun Yat-sen University1 site in 1 country240 target enrollmentFebruary 2016
ConditionsRectal Cancer

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Rectal Cancer
Sponsor
Sixth Affiliated Hospital, Sun Yat-sen University
Enrollment
240
Locations
1
Primary Endpoint
Incidence of major bowel dysfunction
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

Neoadjuvant chemoradiotherapy has been recommended as the standard preoperative treatment for locally advanced rectal cancer. However, preoperative radiotherapy increases the risk of bowel dysfunction after sphincter-preserving surgery, for which patients suffer from incontinence, urgency, and unpredictability defecation problems. Furthermore, preoperative chemoradiotherapy is a potential risk factor of anastomotic leakage and stenosis after rectal cancer surgery.

Unhealthy anastomosis, with both ends of injured bowel segments after pelvic radiation, is a major concern. When conventional surgical procedures would retain part of sigmoid colon that has been included in the radiation target, sphincter-preserving surgery with proximally extended resection margin could provide an intact proximal colon limb for the anastomosis.

It is not known yet whether proximally extended resection improves postoperative bowel function or anastomotic integrity for patients with rectal cancer after neoadjuvant chemoradiotherapy. The proposed study will compare sphincter-preserving surgery with and without proximally extended resection margin, to observe the postoperative bowel function, as well as the incidence of anastomotic complication. This study will examine a new surgical strategy, which potentially benefits the patients undergoing neoadjuvant chemoradiotherapy.

Registry
clinicaltrials.gov
Start Date
February 2016
End Date
December 2028
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Sixth Affiliated Hospital, Sun Yat-sen University
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Age: 18-75 years old
  • ECOG performance status: 0-2
  • Histologically confirmed adenocarcinoma of the rectum
  • Distal border of the tumor located ≤ 12 cm from the anal verge
  • Primary stage T3-4 or any node-positive disease
  • Undergoing long-course 5-fluorouracil based neoadjuvant chemoradiotherapy
  • Conventional fractionated radiotherapy of at least 45 Gy
  • Resectable disease after neoadjuvant chemoradiotherapy
  • No evidence of distant metastasis
  • Amenable to sphincter-preserving surgery

Exclusion Criteria

  • Prior or concurrent malignancies within the past 5 years except for effectively treated squamous cell or basal cell skin cancer, melanoma in situ, or carcinoma in situ of the cervix
  • Synchronous colon cancer
  • History of colorectal resection except appendectomy
  • Acute intestinal obstruction or perforation
  • Multiple visceral resection
  • Abdominoperineal resection
  • American Society of Anesthesiologists (ASA) class Ⅳ or Ⅴ
  • Pregnant or nursing, fertile patients do not use effective contraception
  • Serious cardiovascular disease, uncontrolled infections, or other serious uncontrolled concomitant disease
  • Psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule

Outcomes

Primary Outcomes

Incidence of major bowel dysfunction

Time Frame: at the time of 12 months after the restoration of defunctioning stoma

Low anterior resection syndrome score (LARS score) will be used to assess the bowel function. Number of participants with major LARS will be calculated for the incidence of major bowel dysfunction.

Secondary Outcomes

  • Incidence of anastomotic leakage(up to 6 months postoperatively)
  • 5-year overall survival(5 years)
  • Postoperative mortality(up to 30 days postoperatively)
  • Postoperative morbidity(up to 30 days postoperatively)
  • Quality of life impairment(at the time of 60 months after the restoration of defunctioning stoma)
  • Incidence of major bowel dysfunction(at the time of 60 months after the restoration of defunctioning stoma)
  • 3-year disease free survival(3 years)
  • Incidence of anastomotic haemorrhage(up to 1 month postoperatively)
  • Incidence of intraoperative complication(at the time of surgery)
  • Incidence of anastomotic stenosis(12 months postoperatively)

Study Sites (1)

Loading locations...

Similar Trials